Pilot Study of Cetuximab and the Hedgehog Inhibitor IPI-926 in Recurrent Head and Neck Cancer
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the clinical activity of the combination of ipilimumab (IPI) -926 in
combination with cetuximab in patients with advanced head and neck cancer.